×
0 0 0 0 0 0.0156806842480398 0.0156806842480398 0.0156806842480398
Stock impact report

Epizyme Announces Conference Call to Discuss Phase 2 Tazemetostat Follicular Lymphoma Data

Epizyme, Inc (EPZM)  More Company Research Source: Business Wire
Last epizyme, inc earnings: 8/9 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: epizyme.com
PDF CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call on Friday, June 21, 2019 at 8:30 a.m. ET to discuss updated data from an ongoing Phase 2 study of its lead candidate, tazemetostat, as a monotherapy for patients with relapsed or refractory follicular lymphoma. The data, which will be from a recent June 2019 data cutoff date, will be reported in an oral presentation by Franck Morschhauser, M.D., Ph.D., Centre Hospitalier Régional Universitaire and study investigator, at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland. The details of the presentation and the company’s conference call are listed below: ICML Oral PresentationTitle: Interim update from a Phase 2 multicenter study of tazemetostat, an EZH2 inhibito [Read more]
Impact snapshot Event time: EPZM
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
EPZM alerts
from News Quantified
Opt-in for
EPZM alerts

from News Quantified
Opt-in for
EPZM alerts

from News Quantified